

Rev04
Update: Mar,01,2022

DATASHEET

GRO/MGSA/CXCL1, Human

Cat. No.: Z03079

Product Introduction

Species	Human
Protein Construction	GRO-α (Ala35-Asn107) Accession # P09341
Purity	> 95% as analyzed by SDS-PAGE
Endotoxin Level	< 0.2 EU/ μ g of protein by gel clotting method
Biological Activity	Active, measured in a functional assay using HUVEC cells.
Expression System	CHO
Apparent Molecular Weight	~7.8 kDa, on SDS-PAGE under reducing conditions.
Formulation	Lyophilized after extensive dialysis against PBS.
Reconstitution	It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH ₂ O or PBS up to 100 μ g/ml.
Storage & Stability	Upon receiving, this product remains stable for up to 6 months at lower than -70°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw cycles.

Background

Target Background : GRO- α /MGSA/CXCL1 has chemotactic activity for neutrophils. It may play a role in inflammation and exerts its effects on endothelial cells in an autocrine fashion. All three isoforms of GRO are CXC chemokines that can signal through the CXCR1 or CXCR2 receptors. GRO expression is inducible by serum or PDGF and/or by a variety of inflammatory mediators, such as IL-1 and TNF, in monocytes, fibroblasts, melanocytes and epithelial cells. In certain tumor cell lines, GRO is expressed constitutively.

Synonyms : Growth Regulated Protein/Melanoma Growth Stimulatory Activity; GRO α ; MGSA α ; CXCL1; NAP-3; GRO1; KC (murine); CINC (rat)

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.